Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
* \* r* n; r, n6 k' b. a+ m
+ ^9 [6 g, }5 V! i% n
8 a9 {; C O6 _. ?Sub-category:3 `! j( C+ q$ j# ^0 v* p
Molecular Targets
, a+ u1 j( _4 k2 w1 \) }9 d$ D% s5 s0 p% a- l. R- s/ R9 H8 ?4 w
2 k8 l# K0 {1 H. C
Category:4 |1 {& u& v1 o( r- N
Tumor Biology $ X1 I' O) e r! t" o- C, {
; O g6 w6 p6 h3 x
+ ^+ o7 p2 W8 I- Q9 sMeeting:% H+ [# B! N6 `0 \6 ]* K
2011 ASCO Annual Meeting
0 _: f- L9 a$ B- T6 s3 O
) A# X9 \* z1 W0 b$ d. @( Z: U# g
Session Type and Session Title:& W: t @, j2 z6 Y
Poster Discussion Session, Tumor Biology - I! |4 N, ] L+ s7 H! `* d
! _' I; T, `# P" J2 }0 Q$ o
5 m' z l; b4 g; Q" y4 yAbstract No:
1 A4 k8 \9 m0 u10517
5 |& R8 K1 F& A# o9 Q* ^$ X
3 m1 d5 l/ q* O1 a$ U* M# F; a# K+ Z+ C# [. E9 t
Citation:
9 b. _7 z4 [( W4 D5 \: Y0 ZJ Clin Oncol 29: 2011 (suppl; abstr 10517) . O) y4 S n# t- m, |
/ ?. }+ n) j& X* v9 B
4 c5 y% W' t5 j7 c" P7 hAuthor(s): \ R# S+ L$ H
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , O& R! Q1 p1 [3 M/ N4 O
, @& {. C: a- O4 M; o9 K
) G2 @8 d" O5 F7 F& G
: w' ?, b+ H) T, n3 w6 \" P/ @: E
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( M/ E N7 E' b
% h. \, X4 R* m1 P6 H/ V& LAbstract Disclosures
) a4 _! g. z d% p, V: s) e- a" _8 D# n* s
Abstract:5 _5 ~& F1 d# Z B
+ \# a% y$ P* q( e2 o3 q1 G' x1 |# v9 D7 @: a, M, x" p
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.( Q, ~7 w# N3 i- W; Q) O: r
, a$ o2 _9 N5 E6 m5 |" f( ~5 [ ! E/ c; u* ^, g# w& j, l1 M
|
' v, E R/ c y6 i! R+ r8 [
显身卡
